25 XP   0   0   10

Pharma Mar SAU
Buy, Hold or Sell?

Let's analyse Pharma Mar SAU together

PenkeI guess you are interested in Pharma Mar SAU. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharma Mar SAU. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharma Mar SAU

I send you an email if I find something interesting about Pharma Mar SAU.

Quick analysis of Pharma Mar SAU (30 sec.)










What can you expect buying and holding a share of Pharma Mar SAU? (30 sec.)

How much money do you get?

How much money do you get?
$0.69
When do you have the money?
1 year
How often do you get paid?
45.0%

What is your share worth?

Current worth
$10.97
Expected worth in 1 year
$9.62
How sure are you?
55.0%

+ What do you gain per year?

Total Gains per Share
$-0.66
Return On Investment
-2.4%

For what price can you sell your share?

Current Price per Share
$26.85
Expected price per share
$0 - $
How sure are you?
50%

1. Valuation of Pharma Mar SAU (5 min.)




Live pricePrice per Share (EOD)

$26.85

Intrinsic Value Per Share

$-45.39 - $-10.58

Total Value Per Share

$-34.43 - $0.38

2. Growth of Pharma Mar SAU (5 min.)




Is Pharma Mar SAU growing?

Current yearPrevious yearGrowGrow %
How rich?$193.4m$211m-$4.3m-2.1%

How much money is Pharma Mar SAU making?

Current yearPrevious yearGrowGrow %
Making money$301.9k$13.1m-$12.8m-4,240.9%
Net Profit Margin0.6%25.0%--

How much money comes from the company's main activities?

3. Financial Health of Pharma Mar SAU (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#249 / 1019

Most Revenue
#169 / 1019

Most Profit
#163 / 1019

Most Efficient
#163 / 1019

What can you expect buying and holding a share of Pharma Mar SAU? (5 min.)

Welcome investor! Pharma Mar SAU's management wants to use your money to grow the business. In return you get a share of Pharma Mar SAU.

What can you expect buying and holding a share of Pharma Mar SAU?

First you should know what it really means to hold a share of Pharma Mar SAU. And how you can make/lose money.

Speculation

The Price per Share of Pharma Mar SAU is $26.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharma Mar SAU.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharma Mar SAU, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.97. Based on the TTM, the Book Value Change Per Share is $-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is $0.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.17 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharma Mar SAU.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.41-1.5%0.010.1%0.692.6%0.833.1%0.341.3%
Usd Book Value Change Per Share-0.50-1.9%-0.34-1.3%0.612.3%0.501.9%0.210.8%
Usd Dividend Per Share0.000.0%0.170.6%0.000.0%0.120.4%0.130.5%
Usd Total Gains Per Share-0.50-1.9%-0.16-0.6%0.612.3%0.622.3%0.331.2%
Usd Price Per Share46.26-40.83-68.88-51.72-26.85-
Price to Earnings Ratio-28.17-59.76-31.74-27.02-9.89-
Price-to-Total Gains Ratio-91.77--73.23-169.50-25.42-8.54-
Price to Book Ratio4.22-3.55-5.92-6.30-3.60-
Price-to-Total Gains Ratio-91.77--73.23-169.50-25.42-8.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share26.85
Number of shares37
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.170.12
Usd Book Value Change Per Share-0.340.50
Usd Total Gains Per Share-0.160.62
Gains per Quarter (37 shares)-6.0722.86
Gains per Year (37 shares)-24.2891.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
126-50-34187481
251-100-5835148172
377-150-8253221263
4102-199-10671295354
5128-249-13088369445
6153-299-154106443536
7179-349-178124516627
8204-399-202142590718
9230-449-226159664809
10256-498-250177738900

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%17.03.00.085.0%22.018.00.055.0%25.035.00.041.7%
Book Value Change Per Share0.04.00.00.0%8.04.00.066.7%12.08.00.060.0%20.020.00.050.0%25.035.00.041.7%
Dividend per Share1.00.03.025.0%3.00.09.025.0%7.00.013.035.0%18.00.022.045.0%20.00.040.033.3%
Total Gains per Share1.03.00.025.0%9.03.00.075.0%13.07.00.065.0%22.018.00.055.0%28.032.00.046.7%

Fundamentals of Pharma Mar SAU

About Pharma Mar SAU

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Fundamental data was last updated by Penke on 2024-04-03 00:08:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pharma Mar SAU.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharma Mar SAU earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Net Profit Margin of -16.8% means that $-0.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharma Mar SAU:

  • The MRQ is -16.8%. The company is making a huge loss. -2
  • The TTM is 0.6%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ-16.8%TTM0.6%-17.4%
TTM0.6%YOY25.0%-24.5%
TTM0.6%5Y18.7%-18.2%
5Y18.7%10Y7.3%+11.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.8%-197.2%+180.4%
TTM0.6%-210.4%+211.0%
YOY25.0%-279.3%+304.3%
5Y18.7%-436.8%+455.5%
10Y7.3%-599.3%+606.6%
1.1.2. Return on Assets

Shows how efficient Pharma Mar SAU is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • -2.1% Return on Assets means that Pharma Mar SAU generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharma Mar SAU:

  • The MRQ is -2.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM0.1%-2.2%
TTM0.1%YOY3.4%-3.4%
TTM0.1%5Y4.1%-4.0%
5Y4.1%10Y1.5%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%-13.6%+11.5%
TTM0.1%-12.9%+13.0%
YOY3.4%-11.9%+15.3%
5Y4.1%-14.2%+18.3%
10Y1.5%-16.2%+17.7%
1.1.3. Return on Equity

Shows how efficient Pharma Mar SAU is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • -3.7% Return on Equity means Pharma Mar SAU generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharma Mar SAU:

  • The MRQ is -3.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-3.7%TTM0.1%-3.8%
TTM0.1%YOY6.3%-6.3%
TTM0.1%5Y-431.2%+431.2%
5Y-431.2%10Y-218.9%-212.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.7%-17.0%+13.3%
TTM0.1%-16.1%+16.2%
YOY6.3%-15.4%+21.7%
5Y-431.2%-20.0%-411.2%
10Y-218.9%-21.1%-197.8%

1.2. Operating Efficiency of Pharma Mar SAU.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharma Mar SAU is operating .

  • Measures how much profit Pharma Mar SAU makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • An Operating Margin of -12.8% means the company generated $-0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharma Mar SAU:

  • The MRQ is -12.8%. The company is operating very inefficient. -2
  • The TTM is -3.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-12.8%TTM-3.5%-9.2%
TTM-3.5%YOY24.9%-28.5%
TTM-3.5%5Y17.9%-21.5%
5Y17.9%10Y7.6%+10.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.8%-286.1%+273.3%
TTM-3.5%-224.4%+220.9%
YOY24.9%-288.4%+313.3%
5Y17.9%-475.2%+493.1%
10Y7.6%-624.7%+632.3%
1.2.2. Operating Ratio

Measures how efficient Pharma Mar SAU is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.13 means that the operating costs are $1.13 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pharma Mar SAU:

  • The MRQ is 1.128. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.033. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.128TTM1.033+0.095
TTM1.033YOY0.768+0.264
TTM1.0335Y0.819+0.214
5Y0.81910Y0.923-0.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1282.997-1.869
TTM1.0333.247-2.214
YOY0.7683.766-2.998
5Y0.8195.675-4.856
10Y0.9237.857-6.934

1.3. Liquidity of Pharma Mar SAU.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharma Mar SAU is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.63 means the company has $2.63 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharma Mar SAU:

  • The MRQ is 2.634. The company is able to pay all its short-term debts. +1
  • The TTM is 2.918. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.634TTM2.918-0.283
TTM2.918YOY3.057-0.139
TTM2.9185Y2.492+0.426
5Y2.49210Y1.899+0.593
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6343.930-1.296
TTM2.9184.251-1.333
YOY3.0575.436-2.379
5Y2.4926.045-3.553
10Y1.8996.363-4.464
1.3.2. Quick Ratio

Measures if Pharma Mar SAU is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Quick Ratio of 3.26 means the company can pay off $3.26 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharma Mar SAU:

  • The MRQ is 3.264. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.405. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.264TTM3.405-0.141
TTM3.405YOY3.155+0.249
TTM3.4055Y2.861+0.543
5Y2.86110Y1.989+0.873
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2643.629-0.365
TTM3.4054.065-0.660
YOY3.1555.397-2.242
5Y2.8615.993-3.132
10Y1.9896.277-4.288

1.4. Solvency of Pharma Mar SAU.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharma Mar SAU assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharma Mar SAU to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Pharma Mar SAU assets are financed with 43.3% credit (debt) and the remaining percentage (100% - 43.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharma Mar SAU:

  • The MRQ is 0.433. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.419. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.433TTM0.419+0.014
TTM0.419YOY0.452-0.033
TTM0.4195Y0.633-0.213
5Y0.63310Y0.696-0.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4330.332+0.101
TTM0.4190.334+0.085
YOY0.4520.268+0.184
5Y0.6330.366+0.267
10Y0.6960.390+0.306
1.4.2. Debt to Equity Ratio

Measures if Pharma Mar SAU is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A Debt to Equity ratio of 76.4% means that company has $0.76 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharma Mar SAU:

  • The MRQ is 0.764. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.722. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.764TTM0.722+0.042
TTM0.722YOY0.827-0.106
TTM0.7225Y54.026-53.304
5Y54.02610Y28.707+25.319
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7640.381+0.383
TTM0.7220.390+0.332
YOY0.8270.334+0.493
5Y54.0260.434+53.592
10Y28.7070.466+28.241

2. Market Valuation of Pharma Mar SAU

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pharma Mar SAU generates.

  • Above 15 is considered overpriced but always compare Pharma Mar SAU to the Biotechnology industry mean.
  • A PE ratio of -28.17 means the investor is paying $-28.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharma Mar SAU:

  • The EOD is -16.349. Based on the earnings, the company is expensive. -2
  • The MRQ is -28.168. Based on the earnings, the company is expensive. -2
  • The TTM is 59.755. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.349MRQ-28.168+11.819
MRQ-28.168TTM59.755-87.923
TTM59.755YOY31.739+28.016
TTM59.7555Y27.025+32.730
5Y27.02510Y9.890+17.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.349-2.315-14.034
MRQ-28.168-2.560-25.608
TTM59.755-2.664+62.419
YOY31.739-4.122+35.861
5Y27.025-6.258+33.283
10Y9.890-6.108+15.998
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharma Mar SAU:

  • The EOD is -13.288. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.894. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.170. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.288MRQ-22.894+9.606
MRQ-22.894TTM-4.170-18.724
TTM-4.170YOY-52.337+48.168
TTM-4.1705Y-88.250+84.080
5Y-88.25010Y-45.795-42.455
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.288-3.067-10.221
MRQ-22.894-3.251-19.643
TTM-4.170-3.545-0.625
YOY-52.337-5.595-46.742
5Y-88.250-8.315-79.935
10Y-45.795-8.708-37.087
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharma Mar SAU is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.22 means the investor is paying $4.22 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharma Mar SAU:

  • The EOD is 2.448. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.219. Based on the equity, the company is fair priced.
  • The TTM is 3.547. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.448MRQ4.219-1.770
MRQ4.219TTM3.547+0.672
TTM3.547YOY5.919-2.372
TTM3.5475Y6.302-2.755
5Y6.30210Y3.601+2.701
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4481.905+0.543
MRQ4.2192.111+2.108
TTM3.5472.095+1.452
YOY5.9192.836+3.083
5Y6.3023.443+2.859
10Y3.6013.794-0.193
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharma Mar SAU compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.504-0.337-33%0.614-182%0.498-201%0.207-344%
Book Value Per Share--10.96611.529-5%11.675-6%7.299+50%4.991+120%
Current Ratio--2.6342.918-10%3.057-14%2.492+6%1.899+39%
Debt To Asset Ratio--0.4330.419+3%0.452-4%0.633-32%0.696-38%
Debt To Equity Ratio--0.7640.722+6%0.827-8%54.026-99%28.707-97%
Dividend Per Share---0.173-100%-0%0.120-100%0.127-100%
Eps---0.4110.015-2889%0.690-160%0.835-149%0.343-220%
Free Cash Flow Per Share---0.505-0.437-13%0.435-216%0.758-167%0.337-250%
Free Cash Flow To Equity Per Share---0.886-0.913+3%0.239-471%0.296-399%0.092-1065%
Gross Profit Margin--1.940-0.963+150%0.361+438%0.518+274%3.169-39%
Intrinsic Value_10Y_max---10.583--------
Intrinsic Value_10Y_min---45.391--------
Intrinsic Value_1Y_max--1.000--------
Intrinsic Value_1Y_min---0.489--------
Intrinsic Value_3Y_max--1.434--------
Intrinsic Value_3Y_min---4.994--------
Intrinsic Value_5Y_max---0.025--------
Intrinsic Value_5Y_min---13.328--------
Market Cap470307285.000-74%816022097.820731716873.358+12%1244908471.633-34%935582420.973-13%485396914.725+68%
Net Profit Margin---0.1680.006-3089%0.250-167%0.187-190%0.073-332%
Operating Margin---0.128-0.035-72%0.249-151%0.179-171%0.076-268%
Operating Ratio--1.1281.033+9%0.768+47%0.819+38%0.923+22%
Pb Ratio2.448-72%4.2193.547+19%5.919-29%6.302-33%3.601+17%
Pe Ratio-16.349+42%-28.16859.755-147%31.739-189%27.025-204%9.890-385%
Price Per Share26.850-72%46.26040.833+13%68.882-33%51.719-11%26.851+72%
Price To Free Cash Flow Ratio-13.288+42%-22.894-4.170-82%-52.337+129%-88.250+285%-45.795+100%
Price To Total Gains Ratio-53.267+42%-91.774-73.233-20%169.504-154%25.420-461%8.543-1174%
Quick Ratio--3.2643.405-4%3.155+3%2.861+14%1.989+64%
Return On Assets---0.0210.001-3816%0.034-162%0.041-152%0.015-238%
Return On Equity---0.0370.001-5698%0.063-159%-4.312+11416%-2.189+5747%
Total Gains Per Share---0.504-0.164-67%0.614-182%0.618-182%0.334-251%
Usd Book Value--193438000.000206716500.000-6%211049500.000-8%131914100.000+47%91334875.000+112%
Usd Book Value Change Per Share---0.504-0.337-33%0.614-182%0.498-201%0.207-344%
Usd Book Value Per Share--10.96611.529-5%11.675-6%7.299+50%4.991+120%
Usd Dividend Per Share---0.173-100%-0%0.120-100%0.127-100%
Usd Eps---0.4110.015-2889%0.690-160%0.835-149%0.343-220%
Usd Free Cash Flow---8911019.000-7806966.050-12%7824756.225-214%14010851.465-164%6325283.445-241%
Usd Free Cash Flow Per Share---0.505-0.437-13%0.435-216%0.758-167%0.337-250%
Usd Free Cash Flow To Equity Per Share---0.886-0.913+3%0.239-471%0.296-399%0.092-1065%
Usd Market Cap470307285.000-74%816022097.820731716873.358+12%1244908471.633-34%935582420.973-13%485396914.725+68%
Usd Price Per Share26.850-72%46.26040.833+13%68.882-33%51.719-11%26.851+72%
Usd Profit---7242459.900301901.925-2499%13105251.900-155%14297724.675-151%6175474.240-217%
Usd Revenue--43025671.00041993575.325+2%52133975.075-17%49924382.235-14%47902037.625-10%
Usd Total Gains Per Share---0.504-0.164-67%0.614-182%0.618-182%0.334-251%
 EOD+3 -5MRQTTM+9 -27YOY+7 -275Y+12 -2410Y+12 -24

3.2. Fundamental Score

Let's check the fundamental score of Pharma Mar SAU based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.349
Price to Book Ratio (EOD)Between0-12.448
Net Profit Margin (MRQ)Greater than0-0.168
Operating Margin (MRQ)Greater than0-0.128
Quick Ratio (MRQ)Greater than13.264
Current Ratio (MRQ)Greater than12.634
Debt to Asset Ratio (MRQ)Less than10.433
Debt to Equity Ratio (MRQ)Less than10.764
Return on Equity (MRQ)Greater than0.15-0.037
Return on Assets (MRQ)Greater than0.05-0.021
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Pharma Mar SAU based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than508.972
Ma 20Greater thanMa 5029.494
Ma 50Greater thanMa 10035.097
Ma 100Greater thanMa 20038.660
OpenGreater thanClose26.850
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Income  6,356-4,8571,4993,8375,336-3,7211,615-8,858-7,242
Net Income from Continuing Operations  1,475231,4993,8375,336-3,7211,615-8,858-7,242



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets341,223
Total Liabilities147,785
Total Stockholder Equity193,438
 As reported
Total Liabilities 147,785
Total Stockholder Equity+ 193,438
Total Assets = 341,223

Assets

Total Assets341,223
Total Current Assets252,602
Long-term Assets88,621
Total Current Assets
Cash And Cash Equivalents 60,024
Short-term Investments 102,538
Net Receivables 47,834
Inventory 39,289
Other Current Assets 2,917
Total Current Assets  (as reported)252,602
Total Current Assets  (calculated)252,602
+/-0
Long-term Assets
Property Plant Equipment 47,607
Intangible Assets 1,935
Long-term Assets Other 0
Long-term Assets  (as reported)88,621
Long-term Assets  (calculated)49,542
+/- 39,079

Liabilities & Shareholders' Equity

Total Current Liabilities95,888
Long-term Liabilities51,897
Total Stockholder Equity193,438
Total Current Liabilities
Short-term Debt 14,504
Short Long Term Debt 12,825
Accounts payable 31,308
Other Current Liabilities 25,130
Total Current Liabilities  (as reported)95,888
Total Current Liabilities  (calculated)83,767
+/- 12,121
Long-term Liabilities
Long term Debt 27,036
Capital Lease Obligations 3,808
Long-term Liabilities Other 193
Long-term Liabilities  (as reported)51,897
Long-term Liabilities  (calculated)31,037
+/- 20,860
Total Stockholder Equity
Common Stock11,013
Retained Earnings 142,223
Accumulated Other Comprehensive Income 15
Other Stockholders Equity 40,187
Total Stockholder Equity (as reported)193,438
Total Stockholder Equity (calculated)193,438
+/-0
Other
Capital Stock11,013
Cash and Short Term Investments 162,562
Common Stock Shares Outstanding 17,640
Current Deferred Revenue24,946
Liabilities and Stockholders Equity 341,223
Net Debt -16,656
Net Invested Capital 233,299
Net Working Capital 156,714
Property Plant and Equipment Gross 94,525
Short Long Term Debt Total 43,368



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-03-31
> Total Assets 
0
207,540
206,152
231,050
228,539
211,314
215,986
242,725
238,550
230,823
220,888
227,721
221,028
217,816
212,203
230,490
218,473
199,830
216,484
207,367
201,867
189,370
205,202
220,042
213,559
201,389
205,770
223,109
245,691
211,939
217,991
220,531
209,525
221,137
216,641
222,195
202,710
187,720
185,649
190,618
174,850
157,676
166,103
129,738
112,537
124,705
275,611
352,227
329,731
330,259
345,102
342,542
347,692
368,386
378,028
390,772
379,098
393,259
373,717
358,690
349,412
341,223
341,223349,412358,690373,717393,259379,098390,772378,028368,386347,692342,542345,102330,259329,731352,227275,611124,705112,537129,738166,103157,676174,850190,618185,649187,720202,710222,195216,641221,137209,525220,531217,991211,939245,691223,109205,770201,389213,559220,042205,202189,370201,867207,367216,484199,830218,473230,490212,203217,816221,028227,721220,888230,823238,550242,725215,986211,314228,539231,050206,152207,5400
   > Total Current Assets 
0
124,925
124,934
149,540
147,732
126,386
131,402
157,917
153,753
143,407
133,428
139,527
133,636
129,531
124,195
142,453
130,792
106,431
122,688
113,966
107,960
95,895
111,435
122,430
116,761
101,916
104,992
120,742
140,333
112,135
118,599
122,056
109,847
120,992
113,904
123,647
104,299
93,176
92,188
97,930
88,272
75,110
39,881
66,874
50,751
49,976
202,583
259,470
237,859
245,651
261,420
276,683
280,941
295,231
289,149
274,689
265,939
275,183
257,475
267,839
260,973
252,602
252,602260,973267,839257,475275,183265,939274,689289,149295,231280,941276,683261,420245,651237,859259,470202,58349,97650,75166,87439,88175,11088,27297,93092,18893,176104,299123,647113,904120,992109,847122,056118,599112,135140,333120,742104,992101,916116,761122,430111,43595,895107,960113,966122,688106,431130,792142,453124,195129,531133,636139,527133,428143,407153,753157,917131,402126,386147,732149,540124,934124,9250
       Cash And Cash Equivalents 
0
37,807
29,196
33,686
45,977
37,246
34,017
20,470
22,896
40,595
29,007
24,831
18,825
30,381
19,653
25,125
26,424
18,336
30,432
13,630
14,572
22,458
19,626
22,723
23,898
16,551
14,951
22,943
39,533
7,629
6,550
8,633
10,595
14,290
11,926
19,628
13,670
24,088
15,886
14,677
26,164
22,745
10,385
39,327
23,409
17,638
153,992
208,892
93,222
96,210
106,432
129,587
132,167
113,348
152,255
142,723
129,433
149,813
119,711
76,070
69,975
60,024
60,02469,97576,070119,711149,813129,433142,723152,255113,348132,167129,587106,43296,21093,222208,892153,99217,63823,40939,32710,38522,74526,16414,67715,88624,08813,67019,62811,92614,29010,5958,6336,5507,62939,53322,94314,95116,55123,89822,72319,62622,45814,57213,63030,43218,33626,42425,12519,65330,38118,82524,83129,00740,59522,89620,47034,01737,24645,97733,68629,19637,8070
       Short-term Investments 
0
0
24,565
28,692
26,254
0
26,133
43,205
38,991
25,985
20,437
16,633
23,512
18,944
17,402
24,614
18,074
16,092
8,141
6,062
6,470
6,377
13,648
12,707
12,518
18,960
15,778
7,840
9,641
37,996
36,965
30,803
21,797
18,077
28,188
21,471
17,872
7,671
7,674
4,270
4,265
4,131
3,393
3,394
3,597
3,257
19,612
19,214
104,023
99,306
103,627
87,145
88,947
88,532
69,333
53,973
56,917
32,607
63,416
108,826
104,378
102,538
102,538104,378108,82663,41632,60756,91753,97369,33388,53288,94787,145103,62799,306104,02319,21419,6123,2573,5973,3943,3934,1314,2654,2707,6747,67117,87221,47128,18818,07721,79730,80336,96537,9969,6417,84015,77818,96012,51812,70713,6486,3776,4706,0628,14116,09218,07424,61417,40218,94423,51216,63320,43725,98538,99143,20526,133026,25428,69224,56500
       Net Receivables 
0
55,851
39,325
0
46,503
61,207
41,644
64,742
64,587
42,829
50,350
65,580
60,581
52,151
55,662
61,865
59,080
48,952
53,584
65,445
62,193
44,832
49,945
58,592
54,669
0
42,657
60,635
62,683
0
47,588
55,832
51,544
62,569
43,894
51,717
44,259
24,965
36,510
48,249
32,844
23,549
72,739
11,678
11,682
14,577
16,793
18,282
27,452
27,707
26,850
27,997
26,036
60,255
30,801
32,497
30,536
41,908
24,447
26,488
30,182
47,834
47,83430,18226,48824,44741,90830,53632,49730,80160,25526,03627,99726,85027,70727,45218,28216,79314,57711,68211,67872,73923,54932,84448,24936,51024,96544,25951,71743,89462,56951,54455,83247,588062,68360,63542,657054,66958,59249,94544,83262,19365,44553,58448,95259,08061,86555,66252,15160,58165,58050,35042,82964,58764,74241,64461,20746,503039,32555,8510
       Other Current Assets 
0
4,827
2,770
29,442
2,914
3,894
2,631
2,295
2,661
4,801
3,309
2,411
3,044
2,746
2,730
3,646
1,906
-451
3,142
1,717
1,171
-4
2,420
3,306
1,473
0
2,969
2,145
2,180
0
2,540
2,007
2,912
1,749
4,624
6,169
5,354
3,059
5,271
4,833
5,126
3,146
-56,603
3,386
3,522
5,602
3,461
3,506
4,588
10,495
15,789
21,210
23,252
22,560
21,027
26,906
27,546
23,109
17,283
20,896
21,546
2,917
2,91721,54620,89617,28323,10927,54626,90621,02722,56023,25221,21015,78910,4954,5883,5063,4615,6023,5223,386-56,6033,1465,1264,8335,2713,0595,3546,1694,6241,7492,9122,0072,54002,1802,1452,96901,4733,3062,420-41,1711,7173,142-4511,9063,6462,7302,7463,0442,4113,3094,8012,6612,2952,6313,8942,91429,4422,7704,8270
   > Long-term Assets 
0
82,615
81,218
81,510
80,807
84,928
84,584
84,808
84,797
87,416
87,460
88,194
87,392
88,285
88,008
88,037
87,681
92,948
93,345
93,045
93,844
93,471
93,767
97,612
96,798
99,473
100,778
102,367
105,358
99,804
99,392
98,475
99,678
100,145
102,737
98,548
98,411
94,544
93,461
92,688
86,578
82,566
65,987
62,864
61,786
74,729
73,028
92,757
91,872
84,608
83,681
65,859
66,751
73,155
88,879
116,083
113,159
118,076
116,242
90,851
88,439
88,621
88,62188,43990,851116,242118,076113,159116,08388,87973,15566,75165,85983,68184,60891,87292,75773,02874,72961,78662,86465,98782,56686,57892,68893,46194,54498,41198,548102,737100,14599,67898,47599,39299,804105,358102,367100,77899,47396,79897,61293,76793,47193,84493,04593,34592,94887,68188,03788,00888,28587,39288,19487,46087,41684,79784,80884,58484,92880,80781,51081,21882,6150
       Property Plant Equipment 
0
39,903
39,773
39,343
38,743
39,062
38,243
37,786
37,373
36,570
35,753
35,307
34,498
33,862
32,825
32,348
31,490
29,794
29,290
29,040
28,800
27,959
27,857
28,288
28,686
29,218
30,367
30,678
31,116
30,624
30,946
30,954
31,473
31,141
30,929
30,863
30,978
31,207
31,111
31,333
27,059
26,637
25,899
26,620
26,473
25,797
24,985
25,118
24,990
25,499
26,753
27,180
28,745
30,605
30,639
30,077
27,688
34,715
34,148
39,186
43,006
47,607
47,60743,00639,18634,14834,71527,68830,07730,63930,60528,74527,18026,75325,49924,99025,11824,98525,79726,47326,62025,89926,63727,05931,33331,11131,20730,97830,86330,92931,14131,47330,95430,94630,62431,11630,67830,36729,21828,68628,28827,85727,95928,80029,04029,29029,79431,49032,34832,82533,86234,49835,30735,75336,57037,37337,78638,24339,06238,74339,34339,77339,9030
       Goodwill 
0
2,548
0
0
0
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5480002,5480
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,138
1,022
788
819
779
733
963
1,025
884
978
868
822
1,029
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,0298228689788841,0259637337798197881,0221,138000000000000000000000000000000000
       Intangible Assets 
0
11,769
0
0
0
12,528
12,763
13,232
13,775
14,448
14,955
15,920
16,736
17,325
18,063
18,186
18,552
19,744
20,437
20,840
21,412
22,590
23,019
23,535
24,735
26,288
26,420
27,584
26,128
26,829
26,106
25,382
25,756
24,900
24,148
23,659
23,143
20,212
19,301
18,382
17,443
16,658
5,691
4,763
3,949
6,074
5,287
4,785
0
3,860
0
0
0
3,233
0
0
2,724
2,589
2,403
2,220
2,010
1,935
1,9352,0102,2202,4032,5892,724003,2330003,86004,7855,2876,0743,9494,7635,69116,65817,44318,38219,30120,21223,14323,65924,14824,90025,75625,38226,10626,82926,12827,58426,42026,28824,73523,53523,01922,59021,41220,84020,43719,74418,55218,18618,06317,32516,73615,92014,95514,44813,77513,23212,76312,52800011,7690
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451
451
356
63
4
0
0
0
0
0
0
0
0
0
0
0
56,188
44,090
33,169
32,551
40,807
30,631
39,462
44,736
42,555
60,235
30,613
30,542
47,243
41,727
41,802
41,791
37,890
1
34,261
33,736
34,409
27,443
28,298
28,103
30,556
0
0
0
0
000030,55628,10328,29827,44334,40933,73634,261137,89041,79141,80241,72747,24330,54230,61360,23542,55544,73639,46230,63140,80732,55133,16944,09056,1880000000000046335645145100000000000000000
> Total Liabilities 
0
158,196
160,737
182,055
182,087
170,178
175,507
203,631
201,625
195,963
189,824
198,272
198,244
183,314
183,339
185,503
177,532
161,104
161,945
154,489
149,213
139,935
139,350
154,948
147,781
141,320
139,641
150,581
168,779
138,903
152,521
161,887
153,414
172,642
170,545
179,003
167,480
164,736
164,003
164,484
146,610
140,203
158,606
133,518
121,746
117,249
198,229
248,729
231,581
227,537
217,577
207,688
204,487
190,468
176,227
183,836
166,594
170,302
156,786
148,388
143,217
147,785
147,785143,217148,388156,786170,302166,594183,836176,227190,468204,487207,688217,577227,537231,581248,729198,229117,249121,746133,518158,606140,203146,610164,484164,003164,736167,480179,003170,545172,642153,414161,887152,521138,903168,779150,581139,641141,320147,781154,948139,350139,935149,213154,489161,945161,104177,532185,503183,339183,314198,244198,272189,824195,963201,625203,631175,507170,178182,087182,055160,737158,1960
   > Total Current Liabilities 
0
65,324
68,830
86,752
83,111
71,906
71,033
95,659
102,511
103,319
101,171
101,591
102,526
89,367
92,371
99,611
96,116
87,355
92,117
83,483
82,954
74,058
83,715
91,905
88,585
82,626
84,543
85,244
84,748
70,623
79,400
84,955
77,911
87,164
87,023
91,496
84,697
83,110
85,428
94,577
78,483
72,382
68,641
70,810
60,769
60,439
103,758
108,447
105,723
94,919
83,793
77,334
81,444
86,346
80,648
96,087
89,940
97,320
89,029
85,509
86,625
95,888
95,88886,62585,50989,02997,32089,94096,08780,64886,34681,44477,33483,79394,919105,723108,447103,75860,43960,76970,81068,64172,38278,48394,57785,42883,11084,69791,49687,02387,16477,91184,95579,40070,62384,74885,24484,54382,62688,58591,90583,71574,05882,95483,48392,11787,35596,11699,61192,37189,367102,526101,591101,171103,319102,51195,65971,03371,90683,11186,75268,83065,3240
       Short-term Debt 
0
0
0
35,404
0
0
34,987
45,428
57,181
62,860
57,807
54,453
0
52,686
54,847
53,020
54,458
54,734
56,511
46,556
48,923
41,327
48,874
52,230
50,289
44,466
46,048
40,401
41,741
28,629
35,671
34,655
28,541
27,906
28,737
29,825
27,253
26,395
30,655
42,620
33,140
28,483
34,666
32,522
30,487
31,333
18,562
20,016
18,624
16,783
17,986
17,950
16,159
14,031
14,337
12,742
15,133
14,733
14,854
14,619
14,753
14,504
14,50414,75314,61914,85414,73315,13312,74214,33714,03116,15917,95017,98616,78318,62420,01618,56231,33330,48732,52234,66628,48333,14042,62030,65526,39527,25329,82528,73727,90628,54134,65535,67128,62941,74140,40146,04844,46650,28952,23048,87441,32748,92346,55656,51154,73454,45853,02054,84752,686054,45357,80762,86057,18145,42834,9870035,404000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,489
94,659
80,011
10,942
11,212
11,234
14,684
18,911
13,508
32,852
30,773
28,722
29,655
17,004
18,524
17,051
15,313
16,235
16,152
14,368
12,212
12,183
10,736
13,776
13,125
13,213
12,748
12,777
12,825
12,82512,77712,74813,21313,12513,77610,73612,18312,21214,36816,15216,23515,31317,05118,52417,00429,65528,72230,77332,85213,50818,91114,68411,23411,21210,94280,01194,65995,489000000000000000000000000000000000
       Accounts payable 
0
29,491
0
37,538
0
30,183
0
0
0
32,677
0
0
0
29,879
0
0
0
23,782
29,742
30,074
25,247
22,364
27,655
31,015
28,485
26,070
30,479
36,298
32,546
30,880
36,400
41,397
39,021
36,712
40,885
42,617
36,470
35,830
37,778
41,097
35,731
31,231
23,756
25,182
19,198
16,471
15,002
15,170
15,987
21,039
20,696
15,752
19,160
26,928
26,353
24,689
31,117
27,492
21,075
23,134
21,284
31,308
31,30821,28423,13421,07527,49231,11724,68926,35326,92819,16015,75220,69621,03915,98715,17015,00216,47119,19825,18223,75631,23135,73141,09737,77835,83036,47042,61740,88536,71239,02141,39736,40030,88032,54636,29830,47926,07028,48531,01527,65522,36425,24730,07429,74223,78200029,87900032,67700030,183037,538029,4910
       Other Current Liabilities 
0
35,833
68,830
13,810
83,111
41,723
36,046
50,231
45,330
7,782
43,364
47,138
0
6,802
37,524
46,591
41,658
8,839
5,864
6,853
8,784
10,367
7,186
8,660
9,811
12,090
8,016
8,545
10,461
11,114
7,329
8,903
10,349
22,546
17,401
19,054
20,974
20,885
16,995
10,860
9,612
12,668
10,219
13,106
11,084
12,635
85,196
73,261
71,112
57,097
45,111
43,632
46,125
45,387
6,728
17,366
7,301
19,359
23,187
16,105
17,351
25,130
25,13017,35116,10523,18719,3597,30117,3666,72845,38746,12543,63245,11157,09771,11273,26185,19612,63511,08413,10610,21912,6689,61210,86016,99520,88520,97419,05417,40122,54610,3498,9037,32911,11410,4618,5458,01612,0909,8118,6607,18610,3678,7846,8535,8648,83941,65846,59137,5246,802047,13843,3647,78245,33050,23136,04641,72383,11113,81068,83035,8330
   > Long-term Liabilities 
0
92,872
91,907
95,303
98,976
98,272
104,474
107,972
99,114
92,644
88,653
96,681
95,718
93,947
90,968
85,892
81,416
73,749
69,828
71,006
66,259
65,877
55,635
63,043
59,196
58,694
55,098
65,337
84,031
68,280
73,121
76,932
75,503
85,478
83,522
87,507
82,783
81,626
78,575
69,907
68,127
67,821
89,965
62,708
60,977
56,810
94,471
140,282
125,858
132,618
133,784
130,354
123,043
104,122
95,579
87,749
76,654
72,982
67,757
62,879
56,592
51,897
51,89756,59262,87967,75772,98276,65487,74995,579104,122123,043130,354133,784132,618125,858140,28294,47156,81060,97762,70889,96567,82168,12769,90778,57581,62682,78387,50783,52285,47875,50376,93273,12168,28084,03165,33755,09858,69459,19663,04355,63565,87766,25971,00669,82873,74981,41685,89290,96893,94795,71896,68188,65392,64499,114107,972104,47498,27298,97695,30391,90792,8720
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,895
17,600
10,490
8,878
6,392
6,126
2,665
2,972
2,899
29,217
2,091
2,137
2,028
49,399
97,457
84,209
92,736
97,382
91,073
84,698
68,820
62,219
55,871
49,369
45,085
0
0
0
0
000045,08549,36955,87162,21968,82084,69891,07397,38292,73684,20997,45749,3992,0282,1372,09129,2172,8992,9722,6656,1266,3928,87810,49017,60017,895000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,543
0
0
0
8,749
0
0
0
5,482
0
0
0
5,151
0
0
0
2,807
0
0
0
2,105
0
0
0
1,403
0
0
0
0
00001,4030002,1050002,8070005,1510005,4820008,74900013,543000000000000000000000000000000000
> Total Stockholder Equity
0
49,344
45,415
48,996
46,452
41,136
40,479
39,094
36,925
34,515
33,023
33,052
27,973
39,553
35,399
48,170
44,820
42,330
58,195
56,609
56,385
53,228
69,674
68,932
69,598
63,882
69,945
76,352
80,742
76,874
69,313
62,492
59,968
52,358
49,964
47,064
39,107
26,866
25,532
30,024
32,135
21,373
11,401
129
-5,296
11,374
81,304
107,434
98,150
102,722
127,525
134,854
143,205
177,918
201,801
206,936
212,504
222,957
216,931
210,302
206,195
193,438
193,438206,195210,302216,931222,957212,504206,936201,801177,918143,205134,854127,525102,72298,150107,43481,30411,374-5,29612911,40121,37332,13530,02425,53226,86639,10747,06449,96452,35859,96862,49269,31376,87480,74276,35269,94563,88269,59868,93269,67453,22856,38556,60958,19542,33044,82048,17035,39939,55327,97333,05233,02334,51536,92539,09440,47941,13646,45248,99645,41549,3440
   Common Stock
0
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,1100
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
0
0
0
15
1500019000000000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
296,078
296,096
63,167
306,369
311,298
312,809
312,822
313,388
-266,045
314,934
314,907
314,907
316,415
317,777
317,468
316,732
316,953
317,015
317,474
317,474
317,260
316,834
316,148
315,967
314,542
313,739
323,292
323,292
66,253
65,830
65,028
66,032
65,953
66,141
67,888
66,807
66,821
66,744
67,877
68,759
69,047
69,658
69,057
69,187
69,794
67,851
59,880
36,905
49,839
48,971
48,949
46,978
45,618
49,309
53,273
50,905
55,413
48,587
51,109
46,212
40,187
40,18746,21251,10948,58755,41350,90553,27349,30945,61846,97848,94948,97149,83936,90559,88067,85169,79469,18769,05769,65869,04768,75967,87766,74466,82166,80767,88866,14165,95366,03265,02865,83066,253323,292323,292313,739314,542315,967316,148316,834317,260317,474317,474317,015316,953316,732317,468317,777316,415314,907314,907314,934-266,045313,388312,822312,809311,298306,36963,167296,096296,0780



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue158,153
Cost of Revenue-13,292
Gross Profit144,861144,861
 
Operating Income (+$)
Gross Profit144,861
Operating Expense-150,211
Operating Income-5,350-5,350
 
Operating Expense (+$)
Research Development97,001
Selling General Administrative18,263
Selling And Marketing Expenses23,542
Operating Expense150,211138,806
 
Net Interest Income (+$)
Interest Income4,103
Interest Expense-2,416
Other Finance Cost-0
Net Interest Income1,687
 
Pretax Income (+$)
Operating Income-5,350
Net Interest Income1,687
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-3,623-7,077
EBIT - interestExpense = -7,766
-3,623
3,553
Interest Expense2,416
Earnings Before Interest and Taxes (EBIT)-5,350-1,207
Earnings Before Interest and Taxes (EBITDA)406
 
After tax Income (+$)
Income Before Tax-3,623
Tax Provision--4,760
Net Income From Continuing Ops1,1371,137
Net Income1,137
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses163,503
Total Other Income/Expenses Net1,727-1,687
 

Technical Analysis of Pharma Mar SAU
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharma Mar SAU. The general trend of Pharma Mar SAU is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharma Mar SAU's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharma Mar SAU.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: < < .

The bearish price targets are: .

Tweet this
Pharma Mar SAU Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharma Mar SAU. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharma Mar SAU Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharma Mar SAU. The current macd is -1.68713226.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharma Mar SAU price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharma Mar SAU. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharma Mar SAU price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pharma Mar SAU Daily Moving Average Convergence/Divergence (MACD) ChartPharma Mar SAU Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharma Mar SAU. The current adx is 63.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharma Mar SAU shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Pharma Mar SAU Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharma Mar SAU. The current sar is 30.75.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharma Mar SAU Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharma Mar SAU. The current rsi is 8.97181574. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Pharma Mar SAU Daily Relative Strength Index (RSI) ChartPharma Mar SAU Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharma Mar SAU. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharma Mar SAU price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pharma Mar SAU Daily Stochastic Oscillator ChartPharma Mar SAU Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharma Mar SAU. The current cci is -332.52854484.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pharma Mar SAU Daily Commodity Channel Index (CCI) ChartPharma Mar SAU Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharma Mar SAU. The current cmo is -91.77617421.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharma Mar SAU Daily Chande Momentum Oscillator (CMO) ChartPharma Mar SAU Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharma Mar SAU. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pharma Mar SAU Daily Williams %R ChartPharma Mar SAU Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharma Mar SAU.

Pharma Mar SAU Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharma Mar SAU. The current atr is 0.38601384.

Pharma Mar SAU Daily Average True Range (ATR) ChartPharma Mar SAU Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharma Mar SAU. The current obv is 12,847.

Pharma Mar SAU Daily On-Balance Volume (OBV) ChartPharma Mar SAU Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharma Mar SAU. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Pharma Mar SAU Daily Money Flow Index (MFI) ChartPharma Mar SAU Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharma Mar SAU.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Pharma Mar SAU Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharma Mar SAU based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than508.972
Ma 20Greater thanMa 5029.494
Ma 50Greater thanMa 10035.097
Ma 100Greater thanMa 20038.660
OpenGreater thanClose26.850
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharma Mar SAU with someone you think should read this too:
  • Are you bullish or bearish on Pharma Mar SAU? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharma Mar SAU? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharma Mar SAU

I send you an email if I find something interesting about Pharma Mar SAU.


Comments

How you think about this?

Leave a comment

Stay informed about Pharma Mar SAU.

Receive notifications about Pharma Mar SAU in your mailbox!